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Abstract
Objective: Inappropriate implantable cardioverter defibrillator (ICD) shocks in children and patients
with congenital heart disease (CHD) remain a major complication of device therapy, occurring in as
many as 50% of children with ICDs. New generation devices include algorithms designed to mini-
mize inappropriate shocks. This study aimed to evaluate the effect of new generation ICDs on the
incidence of inappropriate shocks in the pediatric and CHD population.
Design: Retrospective study of patients with CHD or under age 25 receiving ICDs between 2000
and 2015. New generation ICDs were defined as those with Medtronic “SmartShock” algorithms.
Results: Two hundred eight devices were implanted in 146 patients. Rates of inappropriate shocks
were similar between diagnoses (P 5 .71). The rate of inappropriate shock was 15% over median
5.8 years follow-up. In the 36 patients (25%) with new generation ICDs, the rate of inappropriate
shock was 6.3% over 4 years. Comparing old to new generation ICDs, freedom from first inappro-
priate shock was 90.6% versus 97.1% at 1 year and 80.4% versus 97.1% at 3 years (P 5 .01). Lead
fracture was associated with having inappropriate shock (hazard ratio 8.5, P< .0001), and there
was no significant difference between the device groups when lead fractures were excluded. Clini-
cal actions were taken in 69% of patients after initial inappropriate shock (such as medication or
program change, system revision, or explant). When an action was taken, subsequent inappropriate
shock was reduced (5.3% vs 49.2% at 1 year; P 5 .002).
Conclusions: Pediatric and CHD patients are experiencing reduced inappropriate shocks with new
generation ICD systems, though reduced lead fracture may account for this improvement. Clinical
interventions after inappropriate shock favorably impact the subsequent rate of shocks once an
inappropriate shock occurs.
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1 | INTRODUCTION
Inappropriate implanted cardioverter-defibrillator (ICD) shocks in chil-
dren and patients with congenital heart disease (CHD) remain a major
complication of this potentially lifesaving device therapy. Their inci-
dence is as high as 18%–50% in children, often a rate greater than that
for appropriate shocks.1–4 Children and patients with CHD constitute
as little as 1% of the total population with ICDs, and thus the majority
of data available on factors contributing to inappropriate shocks and
approaches to decreasing them are from older populations with differ-
ent clinical characteristics.5–12 Children have been shown to have sig-
nificant morbidity from inappropriate shock therapies, including post-
Abbreviations: CHD, congenital heart disease; HR, hazard ratio; ICD,
implantable cardioverter-defibrillator; IS, inappropriate shock; LF, lead
fracture; NG-ICD, new generation ICD; TWOS, T-wave oversensing.
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traumatic stress disorder, anxiety, depression, and refusal of ther-
apy,13,14 and there has been at least one reported death due to inap-
propriate therapy leading to ventricular fibrillation.15 There has not
been any clear association of inappropriate shocks with patient charac-
teristics, medications, device types, or particular programming, with the
notable exception of now recalled small-caliber lead models in this
population.16–20
Recently manufacturers have incorporated inappropriate shock-
reduction algorithms in the newer generation of devices, and a recent
study suggests that they decrease inappropriate shock rates in adult
patients,21 although their clinical benefit in the pediatric and congenital
population remains to be demonstrated. This single-center retrospec-
tive study aimed to evaluate the impact of new generation ICDs on the
incidence of inappropriate shocks in this population. A secondary aim
was to determine if clinical decisions after an initial inappropriate shock
decreased the rate of subsequent inappropriate therapies.
2 | METHODS
This is a single-center retrospective study of all patients under the age
of 25 years or with CHD, and having Medtronic ICDs followed by our
center between January 1, 2000 and June 30, 2015. The study
received institutional review board approval. Patients were identified
through the University of Michigan Congenital Heart Center device
database and manufacturer remote monitoring database, with addi-
tional data obtained from the electronic medical record. Patients were
excluded if an ICD was implanted at an outside institution without full
availability of data related to the device. Date of last follow up was
determined as date of death, date of last contact, or clinic visit, or June
30, 2015 for current patients. Information gathered included demo-
graphics, disease type, device and lead information, shock events and
characteristics of each shock. “New generation devices” (NG-ICDs)
were defined as recent Medtronic devices with four algorithms explic-
itly devised to reduce inappropriate shocks (“SmartShock” algorithms,
found in Protecta, VivaXT, and Evera models). Medical charts were
reviewed for documentation of each event, and available tracings were
evaluated, in blinded fashion, for appropriateness of therapy. Therapy
was considered appropriate only when ventricular tachyarrhythmias
with cycle length shorter than the programmed cutoff were identified
and received at least one shock.
2.1 | Statistical analysis
Analyses were performed at the patient level and at the device level
separately to account for potentially different functionality of different
devices in the same patient. Cumulative incidence of inappropriate
shocks at both patient and device level was calculated as the number
of first inappropriate shocks during the study period divided by the
total number of patients or devices included in the analysis. Addition-
ally, the rate of inappropriate shocks was also calculated in the device
level as the number of first inappropriate shocks during the study
period divided by the sum of the device-time of each device included
in the analysis, and was reported as per 100 device-years. Freedom
from first inappropriate shock after device implanted was calculated by
Kaplan-Meier method and compared between old versus NG-ICDs
using log-rank test. Univariate Cox regression model was used to iden-
tify factor(s) associated with increased risk of having an inappropriate
shock. Hazard ratio (HR) and its 95% confidence interval (CI) from the
model were reported. Freedom from subsequent inappropriate shock
after first inappropriate shock was also computed by Kaplan-Meier
method and compared with freedom from first inappropriate shock
after device implanted by log-rank test. In addition, freedom from sub-
sequent inappropriate shock was also compared between patients who
had clinical actions taken after an inappropriate shock versus those
who were not using log-rank test. All analyses were performed using
SAS Version 9.4 (SAS Institute Inc., Cary, North Carolina, USA), with
statistical significant set at a P value <.05 using a two-sided test.
3 | RESULTS
3.1 | Patient analysis
There were 146 patients, including 55 (38%) with CHD, 37 (25%) with
cardiomyopathy, and 54 (37%) with primary electrical disease. Males
comprised 58%, and 15% were of non-Caucasian race. Proportions of
inappropriate shocks were similar between diagnostic groups (31%,
28%, 41%, respectively, for CHD, cardiomyopathy, and primary electri-
cal disease; P 5 .71). Median age at device implant was 16.8 years
(Table 1). There were 36 patients (25%) with NG-ICDs. Median follow-
up duration was 5.8 years (range 0.7–14.8 years). Eleven patients (8%)
died during the study period.
Twenty-nine patients (20%) had an inappropriate shock and 23
(16%) had an appropriate shock. Reasons for first inappropriate shock
included supraventricular tachycardias (41%), sinus tachycardia (3%),
lead fracture or noise (31%), T-wave oversensing (TWOS, 24%).
Median time to first inappropriate shock was 0.9 years (interquartile
range [IQR] 0.2–2.0 years), and median time to first appropriate ther-
apy was 1.4 years (IQR 0.3–3.3 years).
Of the 29 patients who received an inappropriate shock, 9 patients
(31%) had a second inappropriate shock. In these patients, the median
time from first to second inappropriate shock was 0.5 years (IQR 17
days to 1.4 years). Non-Caucasian race trended toward significance (P
5 .06) but no other patient factors including sex, diagnosis category, or
age at device implant, were significantly associated with having an
inappropriate shock (Table 1).
3.2 | Device level analysis
Of the 208 ICDs, 32 (15%) delivered an inappropriate shock during the
study period (Table 2). Comparing old and NG-ICD devices as defined
above, freedom from first inappropriate shock significantly decreased
in old devices over time (P 5 .01, Figure 1). Old generation devices
showed an increased risk of delivering inappropriate shocks when com-
pared with NG-ICDs (HR 5.8, 95% CI 1.7–36.0). The overall rate of
inappropriate shocks was 4.1%, that is, 4.1 inappropriate shocks per
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100 device-years. By device type, the rate of old versus NG-ICDs was
4.7 versus 1.3 per 100 device-years, respectively.
The risk of a first inappropriate shock was significantly increased
by the presence of a lead fracture (HR 8.5, 95% CI 4.2–17.3,
P< .0001). Devices in non-Caucasian patients had an increased risk of
inappropriate shock (HR 2.7, 95% CI 1.2–5.6, P5 .01). As in the patient
level analysis, all other factors were found nonsignificant, including sex,
diagnosis, and age at implant (Table 2), and there was no significant dif-
ference in the demographics between the two device groups (Table 3).
During the study period, only two NG-ICDs delivered a shock
inappropriately.
3.3 | Lead fracture analysis
There were 29 total lead fractures, 17 of which (59%) were associated
with an inappropriate shock (P< .0001). Eighteen of the 29 (62%) total
lead fractures occurred in small-caliber Fidelis leads, and 12 of the 17
inappropriate shocks (71%) associated with a lead fracture were from
Fidelis leads. There were two lead fractures that occurred in NG-ICDs,
neither of which were associated with an inappropriate shock, nor
invoked the noise suppression algorithm; one was a Fidelis lead. Nota-
bly both of these were signaled by home monitors and acted upon clin-
ically. When inappropriate shocks associated with fractured leads were
excluded, freedom from first inappropriate shock between old and NG-
ICD devices were not significantly different: 92.8% versus 97.0% at 1
year and 89.9% versus 97.0% at 3 years, respectively (P 5 .13). Non-
Caucasian race, however, was significantly associated with increased
risk of inappropriate shock (HR 5.9, 95% CI 2.1–16.6, P .0001) even
after excluding lead fractures from the analysis.
3.4 | Subsequent inappropriate shocks
Freedom from a second inappropriate shock after a first inappropriate
shock declined more steeply than freedom from a first inappropriate
shock after device implant (P 5 .04, Figure 2).
Clinical actions taken in patients after an inappropriate shock with
the intent to prevent further shocks were assigned to four categories: a
change in medication, ICD system revision, a change in ICD programming
TABLE 2 Device characteristics (N5208 devices)
Inappropriate shock
Characteristics
Overall*
(N5208)
Yes*
(N532)
No*
(N5 176) HR 95% CI P value§
Male sex 125 (60.1) 23 (68.8) 118 (58.5) 1.58 0.77-3.48 .23
Non-Caucasian race 31 (14.9) 9 (28.1) 22 (12.5) 2.68 1.17-5.61 .01
Diagnosis .71
CHD 79 (38.0) 11 (34.4) 68 (38.6) Ref
Cardiomyopathy 48 (23.1) 9 (28.1) 39 (22.2) 1.44 0.59-3.47 .42
Electrical disease 81 (38.9) 12 (37.5) 69 (39.2) 1.09 0.48-2.46 .85
Age at device implanted, years 18.8 (14.7–24.8) 16.3 (12.3–23.1) 19.4 (15.1–25.8) 0.97 0.93-1.00 .07
Type of device† .01
NG-ICD 69 (33.2) 2 (6.3) 67 (38.1) Ref
Old 139 (66.8) 30 (93.8) 109 (61.9) 5.80 1.73-36.0
Abbreviations: HR, hazard ratio; CI, confidence interval; Ref, reference.
*Data are presented as N (%) for categorical variables and median (interquartile range) for continuous variables.
†NG-ICDs are Evera, Protecta and VivaXT. Old Devices are Consulta, Enrust, Gem, Intrinsic, Marquis, Maximo, Secura, Virtuoso.
§P value from univariate Cox regression.
TABLE 1 Patient characteristics (N5146 patients)
Inappropriate shock
Characteristics
Overall*
(N5146)
Yes*
(N529)
No*
(N5 117) HR 95% CI P value§
Male sex 84 (57.5) 20 (69.0) 64 (54.7) 1.83 0.86-4.23 .13
Non-Caucasian race 22 (15.1) 7 (24.1) 15 (12.8) 2.21 0.87-4.93 .06
Diagnosis .71
CHD 55 (37.7) 9 (31.0) 46 (39.3) Ref
Cardiomyopathy 37 (25.3) 8 (27.6) 29 (24.8) 1.39 0.52-3.65 .50
Electrical disease 54 (37.0) 12 (41.4) 42 (35.9) 1.40 0.59-3.43 .45
Age at device implanted, years 16.8 (13.6–24.8) 15.8 (11.7–23.1) 16.8 (14.5–25.6) 0.97 0.94-1.01 .14
Abbreviations: HR, hazard ratio; CI, confidence interval; Ref, reference.
*Data are presented as N (%) for categorical variables and median (interquartile range) for continuous variables.
§P value from univariate Cox regression.
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or discontinuation of ICD therapy. For the 69% of patients (20/29) who
had an initial inappropriate shock in whom such an action was taken, free-
dom from subsequent inappropriate shock was significantly higher than
for those in whom there was no clinical action taken (P5 .002, Figure 3).
None of the four categories had enough power to determine if they were
independently associated with a significant reduction.
4 | DISCUSSION
Inappropriate shocks have tempered enthusiasm for ICDs despite their
demonstrated life-saving potential. Their psychological harm13,14,22,23
and relation even to mortality,15 have made the decision to initiate ICD
therapy in this population clinically perilous.
Four new algorithms for inappropriate shock reduction were incor-
porated in the ICD models designated “new generation” in this study:
One identifies TWOS and suppresses shock therapy when R wave sig-
nals vary in an alternating fashion. Another withholds therapy when
noise on the near-field electrogram is not corroborated by the far-field
electrogram. A third is an improved verification of anti-tachycardia pac-
ing success. Finally, there is a refined morphology and timing algorithm
FIGURE 1 Freedom from first inappropriate shocks by type of
device. By device type, freedom from first inappropriate shocks
were 90.6% versus 97.1% at 1 years and 80.4% versus 97.1% at 3
years (Old vs New; P 5 .01 from log-rank test; hazard ratio 5.80
and 95% CI 1.73–36.0)
TABLE 3 Patient characteristics by device type (N5208 devices)
Type of device†
Characteristics
NG-ICD
(N569)
Old
(N5139) P value¥
Male sex 42 (60.9) 83 (59.7) .87
Non-Caucasian race 12 (17.4) 19 (13.7) .48
Diagnosis .10
CHD 24 (34.8) 55 (39.6)
Cardiomyopathy 22 (31.9) 26 (18.7)
Electrical disease 23 (33.3) 58 (41.7)
Age at device
implanted, years
20.4 (15.7–26.0) 17.4 (14.0–24.4) .11
*Data are presented as N (%) for categorical variables and median (inter-
quartile range) for continuous variable.
†NG-ICDs are Evera, Protecta and VivaXT. Old Devices are Consulta,
Enrust, Gem, Intrinsic, Marquis, Maximo, Secura, Virtuoso.
¥P value from chi-square test for categorical variables and Wilcoxon
rank-sum test for continuous variable.
FIGURE 2 Freedom from second inappropriate shocks versus
Freedom from first inappropriate shocks. Freedom from 1st
inappropriate shock after implant was significantly higher than
freedom from second inappropriate shock after first inappropriate
shock (92.7% vs 82.1% at 1 year, 85.1% vs 77.2% at 3 years, and
83.0% vs 67.6% at 5 years; P 5 .04 from log-rank test)
FIGURE 3 Freedom from subsequent inappropriate shocks
following clinical actions. Freedom from subsequent inappropriate
shocks in patients with any action taken after the first
inappropriate shock was significantly higher than those without
(94.7% vs 50.8% at 1 year, P 5 .002 from log-rank test)
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devised to distinguish ventricular tachycardia from others. This combi-
nation of algorithms reduced inappropriate shocks in an adult cohort.21
While the data in this series did not demonstrate the beneficial
implementation of these new algorithms, the important finding of our
study was that pediatric and CHD patients are experiencing signifi-
cantly reduced inappropriate shocks with newer generation ICD sys-
tems compared with older ICD models.
The rate of inappropriate shocks from all devices in our study was
4.1 per 100 device-years, within the range previously reported for chil-
dren and patients with CHD: 3.5–9.8 per 100 device years.1–4,24 When
isolating the new generation devices, however, the incidence of inap-
propriate shocks was much lower: 6.3% over 4 years follow-up, or 1.3
per 100 device-years.
Although it might be presumed that this difference was due to
new algorithms which prevent inappropriate shock therapy, we could
not confirm this. We found the predominant correlate of the reduced
inappropriate shocks was reduced lead fractures. The older generation
devices in this study coincided with use of the Medtronic Sprint Fidelis
lead (2004–2007). The literature regarding inappropriate shocks in this
population largely reflects the Fidelis era as well.25,26 Widely adopted
by our and other pediatric/congenital centers due to its smaller caliber,
the lead failed at a particularly high rate in young patients, usually due
to pace-sense conductor failures, which commonly resulted in over-
sensing.20 Neither of the lead fractures in the NG-ICD group led to an
inappropriate shock. One might suspect that the algorithms in the NG-
ICDs accounted for improved performance in the setting of a lead frac-
ture; however, the noise suppression algorithm was apparently not
invoked on specific review. The small number of lead fractures in NG-
ICDs resulted in an underpowered analysis of the relationship between
shocks to lead fractures.
Even relatively recent studies have reported higher rates of inap-
propriate shocks in this patient group. In one recent report, a rate of
inappropriate shocks nearly as low was described (9.7% over median
42 month follow-up; on our calculations 3.5 per 100 device-years), but
multivariate analysis failed to identify factors associated with inappro-
priate shocks.24 Though the data did not point conclusively to a cause,
the authors attributed their relatively favorable rate of inappropriate
shocks to their institutional practices of extended arrhythmia detection
time and use of beta blockers. Newer generation devices were not spe-
cifically assessed.
In our secondary aim to evaluate clinical interventions after inap-
propriate shock, freedom from first inappropriate shock declined more
gradually than that from a second inappropriate shock. Clinical inter-
ventions taken after inappropriate shocks—which included medication
change, explant, lead revision, and programming change—when
grouped together, significantly decreased the risk of subsequent inap-
propriate shock. Identifying and acting on a cause of an inappropriate
shock was clearly better than not doing so, as has been appreciated in
an adult study.10
Non-Caucasian race was identified as the only correlate of inap-
propriate shock when lead fractures were excluded from analysis, a
finding not seen in other studies on this subject. This entirely unex-
pected observation may reflect availability or quality of care based on
socioeconomic status. Particularly given the disparities seen in initiation
of ICD therapy,27,28 among many gaps in healthcare distribution in the
United States, this finding warrants further evaluation.
This study was limited by its retrospective design and local practice
patterns. Further limitations include the following: follow-up was not
uniform due to care sometimes at affiliate centers, and certain pro-
gramming data were not available on all patients. Although there was
an evolution in tachycardia detection programming observed nationally
in response to data published during the study period,29 the documen-
tation of detection programming in our study was inadequate for analy-
sis of changes in tachycardia detection programming over time.
Improvements in home monitoring over this time also represent a secu-
lar trend whose impact on the results could not be quantified. Notably,
the two lead fractures in the NG-ICDs were all detected by remote
monitor transmissions, and neither resulted in inappropriate shock. Bet-
ter remote ICD surveillance in the NG-ICD era may have contributed
to more prompt identification of, and response to other impending
device problems.
In conclusion, the current era of ICD care for children and patients
with CHD is characterized by a marked reduction in inappropriate
shocks compared with prior years likely due to improved lead perform-
ance. Racial disparity in inappropriate shocks warrants further atten-
tion. This study suggests an improved balance between reward and risk
for ICDs in the pediatric and congenital population.
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